Online inquiry

IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6467MR)

This product GTTS-WQ6467MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens; Humanized
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6467MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3280MR IVTScrip™ mRNA-Anti-alpha toxin&lukE, ASN-1(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ASN-1
GTTS-WQ5001MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA C4G1
GTTS-WQ11636MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MGD-013
GTTS-WQ9035MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ6751MR IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DS 992
GTTS-WQ5446MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CDA 1
GTTS-WQ2315MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ALXN6000
GTTS-WQ13882MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-1979
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW